Forward P/S Multiple: MEI Pharma (MEIP)

Corporate emblem and logo of MEI Pharma Inc (MEIP)

Production optimization via outsourcing to contract manufacturing organizations is driving growth, as confirmed by the expected P/S value on the GURU.Markets chart, where 0.30 reflects today's metric value. The resilience of MEI Pharma, Inc. (MEIP) is based on a diverse range of hematology programs at various stages. High financial barriers to entry and patent protection for innovations create a robust moat against third-party players in the oncology sector.

MEI Pharma Inc - MEIP Market Cap to Expected Sales Ratio (period 07/04/2022 - 11/13/2024)

Financial and market metric breakdowns for MEI Pharma Corporation (MEIP)

- market price and analyst price targets:
Price Chart MEI Pharma|MEIP - Consensus Target
- company stock exchange capitalization indicators:
Market Capitalization MEI Pharma Corporation|MEIP - Total Enterprise Value
- issuer book value statistics:
Book Value per Share MEI Pharma|MEIP - Book Valuation of Business|Market Cap to Net Assets Ratio meipharma.com|MEIP - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity MEI Pharma, Inc.|MEIP - Long-Term Liabilities to Equity|Short-Term Debt to Capital MEI Pharma, Inc.|MEIP - Aggregate Debt Obligations|Debts to Book Capitalization MEI Pharma Corporation|MEIP - Company Long-Term Debts|Company Short-Term Debt MEI Pharma|Quick Liquidity meipharma.com
- financial results and valuation multiples details:
MEIP - Net Income|Projected Future Earnings MEI Pharma, Inc.|MEIP - P/E Multiple|Projected Price to Earnings MEI Pharma Corp|MEIP - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple MEI Pharma Corporation|MEIP - Operating income before deduction of amortization|Earnings per share for the last twelve months MEI Pharma|MEIP - Earnings per share for the last 12 months|Quarterly EPS earnings growth meipharma.com|MEIP - Net earnings per share growth this year|Expected earnings per share growth for next year MEI Pharma, Inc.
- sales volume and revenue indicators:
MEIP - Company Gross Revenue|Company Projected Revenue MEI Pharma|MEIP - Market Cap to Revenue|Forward P/S Multiple MEI Pharma Corporation
Summary company analysis:MEI Pharma MEIP
Original product of MEI Pharma Corporation

For MEI Pharma, Inc. (MEIP), this indicator correlates market capitalization with projected revenue, determining the premium for future growth amid high risks of clinical failures. An analysis of the forward P/S multiple allows for an assessment of the company's valuation resilience against potential liquidity depletion, where inflated values signal a critical dependence of the share price on the success of oncology drug development.

Competitors of MEI Pharma, Inc.

Price-to-Projected Revenue Ratio TG Therapeutics TGTX|ACLX - Forward Price-to-Revenue Multiple|Disc Medicine Corp - Forward P/S Multiple|Market Cap to Future Revenue Ratio Syndax Corp|KURA: Forward P/S Multiple|ADCT - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple FHTX|VOR: Forward Price to Sales|Price-to-Projected Revenue Ratio Nkarta, Inc. (NKTX)|COEP: Future Price to Revenue|Forward P/S Multiple ATNM (Actinium Pharmaceuticals)|Forward Price to Sales ESLA|CASI Pharmaceuticals, Inc - Forward P/S Multiple|MRKR - Forward P/S Multiple|IN8bio, Inc (INAB) - Price-to-Projected Revenue Ratio|Eterna Therapeutics Inc. - Forward Price to Sales|Price-to-Projected Revenue Ratio GT Biopharma, Inc.|Forward Price-to-Revenue Multiple Aptose (APTO)|Forward P/S Multiple BPTH|Forward P/S Multiple vincerx.com (VINC)